Dr. Pouliot obtained doctorates in medicine (M.D.) and in Physiology-Endocrinology (Ph.D.) from Laval University. After completing a residency in Urology (F.R.C.S.C.), he did a post-doctoral fellowship in Urologic Oncology and molecular imaging at the University of California, Los Angeles (UCLA). Since 2010, he has practiced as a urologist-oncologist in the Quebec City University Hospital Center. He is also an associate professor in Laval University’s Department of surgery. He oversees the CHU de Québec multidisciplinary clinic in castration-resistant prostate cancer. In 2014, he was the recipient of the Prostate Cancer Canada/Movember Rising Star Award. He is also the recipient of the FRQS Clinical Research Scholars Junior 1 and 2 and Senior. His clinical and preclinical research interests include the detection and characterization of high risk, advanced and metastatic prostate cancers using transcriptional amplification systems or positron emission tomography (PET) with tracers such as fluoro-deoxyglucose or PSMA ligands (PyL, MP-1404).  He is also involved in the development of new radioligand therapeutics.

His research program has four aims: 1) To develop a dynamic imaging method based on a transcriptional amplification system allowing the sensitive detection of a luminescent reporter gene under the control of prostate cancer specific promoters. This microscopy method will allow predicting the patient’s response to antiandrogen treatments. 2) Use positron emission tomography imaging (PET/CT) as a quantitative method to identify the very high risk prostate cancer and to assess metastasis individual response, in addition to global response to systemic treatment. 3) Develop a prostate cancer immunotherapy based on a transcriptional amplification system specific to prostate cancer. This vaccine vector will allow the introduction of recombinant genes in patient’s prostate cancer cells to induce an efficient immune response against cancer cells.  4) Characterize the androgen receptor (AR) activation in castration resistant prostate cancer patients. This project aims to determine which steroids activate the AR under chemical castration and to identify new AR interacting partners using proteomics.

L'Hôtel-Dieu de Québec
6, rue McMahon
0624
Québec, Québec
Canada G1R 2J6
99 entries « 1 of 10 »

Couture F, Finelli T, Breau RH, Mallick R, Bhindi B, Tanguay S, Kapoor A, Rendon RA, Pouliot F, Lavallée L, Fairey AS, So A, Richard PO

The increasing use of renal tumor biopsy amongst Canadian urologists: When is biopsy most utilized?

Journal Article

Urol Oncol, 39 (8), 2021.

Abstract | Links:

Tremblay S, Summers-Trasiewicz L, Pouliot F, Crook JM, Ding K, Klotz L, Toren P

Reply by Authors.

Journal Article

J Urol, 2021.

| Links:

Zhang H, Koumna S, Pouliot F, Beauregard JM, Kolinsky M

PSMA Theranostics: Current Landscape and Future Outlook.

Journal Article

Cancers (Basel), 13 (16), 2021.

Abstract | Links:

Saad F, Hotte SJ, Finelli A, Malone S, Niazi T, Noonan K, Shayegan B, So AI, Danielson B, Basappa NS, Cagiannos I, Canil C, Delouya G, Fernandes R, Ferrario C, Gotto GT, Hamilton RJ, Izard JP, Kapoor A, Khalaf D, Kolinsky M, Lalani AK, Lavallee LT, Morash C, Morgan SC, Ong M, Pouliot F, Rendon RA, Yip S, Zardan A, Park-Wyllie L, Chi K

Results from a Canadian consensus forum of key controversial areas in the management of advanced prostate cancer: Recommendations for Canadian healthcare providers.

Journal Article

Can Urol Assoc J, 2021.

Abstract | Links:

Kokorovic A, So AI, Serag H, French C, Hamilton RJ, Izard JP, Nayak JG, Pouliot F, Saad F, Shayegan B, Aprikian A, Rendon RA

Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies - Executive summary.

Journal Article

Can Urol Assoc J, 15 (6), 2021.

| Links:

Kokorovic A, So AI, Serag H, French C, Hamilton RJ, Izard JP, Nayak JG, Pouliot F, Saad F, Shayegan B, Aprikian A, Rendon RA

Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies.

Journal Article

Can Urol Assoc J, 15 (6), 2021.

| Links:

Otis-Chapados S, Goulet CR, Dubois G, Lavallee E, Dujardin T, Fradet Y, Lacombe L, Lodde M, Tiguert R, Toren P, Fradet V, Beauregard JM, Buteau FA, Pouliot F

F-Fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) is accurate for high-grade prostate cancer bone staging when compared to bone scintigraphy.

Journal Article

Can Urol Assoc J, 2021.

Abstract | Links:

Saad F, Aprikian A, Finelli A, Fleshner NE, Gleave M, Kapoor A, Niazi T, North SA, Pouliot F, Rendon RA, Shayegan B, Sridhar SS, So A, Usmani N, Vigneault E, Chi KN

2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC).

Journal Article

Can Urol Assoc J, 15 (2), 2021.

| Links:

Sun R, Breau RH, Mallick R, Tanguay S, Pouliot F, Kapoor A, Lavallee LT, Finelli A, So AI, Rendon RA, Fairey AS, Lattouf JB, Kawakami J, Bhindi B, Basappa NS, Wood LA, Bjarnason GA, Heng DYC, Bansal R

Prognostic impact of paraneoplastic syndromes on patients with non-metastatic renal cell carcinoma undergoing surgery: Results from Canadian Kidney Cancer information system.

Journal Article

Can Urol Assoc J, 15 (4), 2021.

Abstract | Links:

Hotte SJ, Finelli A, Chi KN, Canil C, Fleshner N, Kapoor A, Kolinsky M, Malone S, Morash C, Niazi T, Noonan KL, Ong M, Pouliot F, Shayegan B, So AI, Sorabji D, Hew H, Park-Wyllie L, Saad F

Real-world management of advanced prostate cancer: A description of management practices of community-based physicians and prostate cancer specialists.

Journal Article

Can Urol Assoc J, 15 (2), 2021.

Abstract | Links:

99 entries « 1 of 10 »
Signaler des ajouts ou des modifications

Active projects

  • National Program on Radioligand Therapy for Prostate Cancer, from 2018-01-01 to 2022-12-31
  • Optimiser les soins des patients atteints du cancer de la prostate résistant à la castration en utilisant une stratégie de triple traceur en imagerie moléculaire et en radiothérapieléculaire et en radiothérapie ciblée, from 2018-04-01 to 2022-06-30
  • Surveillance of Complex Renal Cysts: The SOCRATIC study, from 2019-10-01 to 2028-09-30
  • Utilisation de l’imagerie moléculaire par microscopie à bioluminescence ou par tomographie par émission de positrons afin d’optimiser les stratégies thérapeutiques des patients atteints de cancers urologiques, from 2019-07-01 to 2023-06-30

Recently finished projects

  • Characterizing high-risk prostate tumor heterogeneity at single cell level to identify castration-resistant prostate cancer progression molecular profile , from 2019-07-29 to 2020-03-31
  • CUASF-BCC Research Grant Program , from 2020-06-06 to 2021-06-05
  • Modeling Prostate Cancer in 30 using tissue engineering , from 2019-09-11 to 2020-09-10
  • Projet de recherche sur le cancer de la prostate intitulé Ironman , from 2020-03-24 to 2021-03-23
  • Support statistique pour la recherche en Urologie-oncologie, from 2019-03-25 to 2020-03-24
Data provided by the Université Laval research projects registery